Sage Therapeutics, Inc. SAGE
We take great care to ensure that the data presented and summarized in this overview for Sage Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SAGE
View all-
Vanguard Group Inc Valley Forge, PA5.75MShares$67.8 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$64.6 Million1.65% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$57.6 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.75MShares$56 Million0.02% of portfolio
-
State Street Corp Boston, MA4.49MShares$52.9 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.47MShares$52.6 Million1.31% of portfolio
-
Morgan Stanley New York, NY1.26MShares$14.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.19MShares$14 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY1.15MShares$13.6 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.03MShares$12.1 Million0.01% of portfolio
Latest Institutional Activity in SAGE
Top Purchases
Top Sells
About SAGE
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SAGE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 13
2024
|
Kimi Iguchi CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+12.11%
|
-
|
Feb 13
2024
|
Christopher Benecchi Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+41.0%
|
-
|
Feb 13
2024
|
Laura Gault Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+49.5%
|
-
|
Feb 13
2024
|
Anne Marie Cook SVP, GC & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+30.88%
|
-
|
Jan 02
2024
|
Kimi Iguchi CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,642
+2.28%
|
$1,642
$1.36 P/Share
|
Nov 28
2023
|
Anne Marie Cook SVP, GC & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,174
-7.88%
|
$22,306
$19.27 P/Share
|
Nov 28
2023
|
Anne Marie Cook SVP, GC & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+21.18%
|
-
|
Nov 28
2023
|
Jeffrey M Jonas |
SELL
Payment of exercise price or tax liability
|
Direct |
3,935
-2.98%
|
$74,765
$19.27 P/Share
|
Nov 28
2023
|
Jeffrey M Jonas |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+7.04%
|
-
|
Nov 28
2023
|
Kimi Iguchi CFO & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
943
-1.35%
|
$17,917
$19.27 P/Share
|
Nov 28
2023
|
Kimi Iguchi CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+4.78%
|
-
|
Aug 09
2023
|
Elizabeth Barrett |
BUY
Open market or private purchase
|
Direct |
2,000
+40.0%
|
$36,000
$18.64 P/Share
|
May 09
2023
|
Elizabeth Barrett |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$50,000
$50.5 P/Share
|
Mar 15
2023
|
Kimi Iguchi CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+4.38%
|
$3,000
$1.36 P/Share
|
Feb 23
2023
|
Kimi Iguchi CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+0.4%
|
$250
$1.36 P/Share
|
Feb 21
2023
|
Kimi Iguchi CFO & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+1.19%
|
$750
$1.36 P/Share
|
Feb 10
2023
|
Jeffrey M Jonas |
SELL
Open market or private sale
|
Direct |
11,643
-4.45%
|
$512,292
$44.69 P/Share
|
Feb 10
2023
|
Jeffrey M Jonas |
BUY
Exercise of conversion of derivative security
|
Direct |
11,643
+8.01%
|
$0
$0.45 P/Share
|
Feb 03
2023
|
Christopher Benecchi Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,119
-28.72%
|
$93,236
$44.16 P/Share
|
Feb 03
2023
|
Christopher Benecchi Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+47.77%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 64.8K shares |
---|---|
Open market or private purchase | 2K shares |
Exercise of conversion of derivative security | 1.64K shares |
Payment of exercise price or tax liability | 6.05K shares |
---|